Structure Therapeutics down ahead of weight-loss drug data

Structure Therapeutics

08/12/2025 11:51

** Shares of Structure Therapeutics GPCR.O falls 1.4% to $34.1 premarket

** The drug developer on December 8 is set to release data from a study evaluating its experimental drug aleniglipron, a once-daily oral for the treatment of obesity

** The current landscape for obesity treatments includes Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound both of which dominate the market

** Viking Therapeutics' experimental weight-loss pill VK2735 previously failed to surpass Wall Street expectations in August

** As of last close, GPCR stock was up 27.4% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))